All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What does the FIGARO trial reveal about predictors of outcome post-transplant.
What does the FIGARO trial reveal about predictors of outcome post-transplant?
Craddock begins by outlining the trial aims and design, which investigated the use of the FLAMSA-Bu conditioning regimen in adult patients with AML. Craddock outlines the study results, noting that the presence of pretransplant measurable residual disease (MRD) is still associated with increased risk of relapse, and the most important predictor of outcome. Finally, Craddock discusses full donor T-cell chimerism, and reduced intensity conditioning (RIC) allograft strategies and mechanisms.
Your opinion matters
Evaluating predictive factors for post-HSCT survival in secondary AML
Patients with secondary acute myeloid leukemia (sAML) have poor clinical outcomes, even after intensive chemotherapy, and allogeneic hematopoietic stem cell transplantation (HSCT)...
Editorial theme | An introduction to the use of transplantation for the treatment of AML
This article will look at the different stem cell sources used for HSCT, the patients selected for an HSCT, and the current major issues in the pre- and...
Subscribe to get the best content related to AML delivered to your inbox